首页> 外文OA文献 >A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

【2h】

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

机译：II期关于高级肝细胞癌患者的Met抑制剂Capmatinib（Inc280）的疗效和安全性研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Shukui Qin; Stephen Lam Chan; Wattana Sukeepaisarnjaroen; Guohong Han; Su Pin Choo; Virote Sriuranpong; Hongming Pan; Thomas Yau; Yabing Guo; Minshan Chen; Zhenggang Ren; Jianming Xu; Chia-Jui Yen; Zhong-Zhe Lin; Luigi Manenti; Yi Gu; Yongjian Sun; Ralph Tiedt; Lu Hao; Wenjie Song; Tawesak Tanwandee;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma [J] . Therapeutic advances in medical oncology. . 2020,第12期

机译：II期的误诊研究了Met抑制剂Capmatinib（Inc280）在先进的肝细胞癌患者中的疗效和安全性研究
2. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma [J] . Shukui Qin, Stephen Lam Chan, Wattana Sukeepaisarnjaroen, Therapeutic advances in medical oncology. . 2019,第12期

机译：II期关于高级肝细胞癌患者的Met抑制剂Capmatinib（Inc280）的疗效和安全性研究
3. A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma [J] . Lim Ho Yeong, Heo Jeong, Choi Hye Jin, Clinical cancer research: an official journal of the American Association for Cancer Research . 2014,第23期

机译：II期研究MEK抑制剂Refametinib（Bay 86-9766）加入索拉芬患者的患者的疗效和安全性的疗效和安全性研究患有不可切除的肝细胞癌的患者
4. Diffusion-weighted MR imaging of advanced hepatocellular carcinoma treated with the oral multikinase inhibitor Sorafenib [C] . C. Schraml, N.F. Schwenzer, H. Rempp, World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：口服多激酶抑制剂索拉非尼治疗晚期肝癌的扩散加权MR成像
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Erratum to A phase II study of the efficacy and safety of the METinhibitor capmatinib (INC280) in patients with advanced hepatocellularcarcinoma [O] . 2020

机译：勘误到MET疗效和安全性的II期研究抑制剂卡马替尼（INC280）用于晚期肝细胞癌患者癌
7. MINI01.03: Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET+ NSCLC [O] . Todd M. Bauer, Martin Schuler, Rossana Berardi, 2016

机译：mini01.03：阶段（pH）我研究CMET抑制剂CAPMATINIB（INC280）在先进的CMET + NSCLC患者中的安全性和有效性

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

著录项

引文网络

相似文献

相关主题

期刊订阅